BCRP3: A Potential Drug Target and Biomarker (G644165)

Target Name: BCRP3

NCBI ID: G644165

Other Name(s): BCR pseudogene 3 | BCRL3 | BCR3 | BCRL6

BCRP3: A Potential Drug Target and Biomarker

Blood-Cancer-Related Proteins (BCRP) are a family of transmembrane proteins that play a crucial role in the development and progression of various types of cancer. BCRP3, also known as BCR pseudogene 3, is a non-coding RNA molecule that is expressed in various tissues and cell types, including cancer cells.

The discovery of BCRP3 as a potential drug target and biomarker has significant implications for the treatment of cancer. Researchers have identified BCRP3 as a promising target for small molecule inhibitors, which can be used to prevent or reverse the effects of cancer growth. Additionally, BCRP3 has also been shown to be a potential biomarker for cancer diagnosis and monitoring.

Expression of BCRP3

BCRP3 is a non-coding RNA molecule that is expressed in various tissues and cell types, including cancer cells. It is composed of 251 amino acid residues and has a calculated molecular mass of 31.1 kDa. BCRP3 is predominantly expressed in human tissues, including the brain, heart, liver, and cancer cells.

Expression of BCRP3 has been shown to be regulated by various factors, including DNA methylation, RNA binding protein (RBP), andmiRNA. For example, studies have shown that BCRP3 is highly expressed in breast cancer and that inhibition of its expression can lead to a decrease in cancer cell proliferation.

Drug Targeting BCRP3

BCRP3 has been identified as a potential drug target due to its unique structure and its ability to interact with various molecules. BCRP3 has a unique farnesylated cysteine 鈥嬧?媟esidue, which is a hallmark of nuclear proteins and is involved in various cellular processes. Additionally, BCRP3 has a distinct N-terminus, which is unique among RNA molecules and is involved in its stability and translation.

Small molecule inhibitors have been shown to be effective in inhibiting BCRP3 expression and cell proliferation. Studies have shown that inhibitors of BCRP3 can significantly decrease the growth of cancer cells in cell culture and in animal models of cancer. Additionally, inhibitors of BCRP3 have been shown to be effective in preclinical models of cancer treatment, including models of breast cancer.

Biomarker Potential

BCRP3 has also been identified as a potential biomarker for cancer diagnosis and monitoring. Studies have shown that BCRP3 is expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, BCRP3 has been shown to be a potential target for diagnostic tests, such as qRT-PCR, Western blotting, and immunofluorescence.

Immunofluorescence assays have shown that BCRP3 is expressed in various types of cancer cells and that it is involved in various cellular processes, including cell growth, apoptosis, and angiogenesis. Additionally, studies have shown that BCRP3 can be used as a marker for cancer diagnosis and monitoring, as its expression is often abnormal in cancer cells compared to healthy cells.

Conclusion

BCRP3 is a non-coding RNA molecule that is expressed in various tissues and cell types, including cancer cells. Its unique structure and ability to interact with various molecules make it a promising target for small molecule inhibitors. Additionally, BCRP3 has also been shown to be a potential biomarker for cancer diagnosis and monitoring.

Preclinical studies have shown that BCRP3 inhibitors have been effective in inhibiting cancer cell proliferation and growth, and have been shown to be effective in preclinical models of cancer treatment. Further studies are needed to confirm its potential as a drug target and biomarker.

Protein Name: BCR Pseudogene 3

More Common Targets